Clinical trials: Newly Diagnosed Mantle Cell Lymphoma
Mantle Cell Lymphoma
Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy
This is an observational study aimed to analyze the effectiveness of treatment of patients with newly dg. mantle cell lymphoma not eligible for high-dose therapy and autologous stem cell transplantation.
- Trial name
- NCT03054883
- Volunteers
- 73 people
- Sponsor
- Czech Lymphoma Study Group
Untreated Mantle Cell Lymphoma
Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma
The proposed study is a prospective, single-center, single-arm and open-ended phase II study in patients over the age of 18 with previously untreated mantle cell lymphoma(MCL).
- Trial name
- NCT05504603
- Testing
- zanubrutinib and rituximab, BEAM pretreatment, zanubrutinib maintenance
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Newly Diagnosed Mantle Cell Lymphoma
A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
An open-label, single-arm, multicenter, prospective clinical study of Hanlikang and BTK inhibitors in the treatment of newly diagnosed mantle cell lymphoma
- Trial name
- NCT05506410
- Testing
- Rituximab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhengzhou University
Mantle Cell Lymphoma
Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)
1. Induction chemotherapy 1) RCHOP(Rituximab+Cyclophosphamide+Doxorubicin+Vincristine+Prednisone) 2) VR-CAP (Bortezomib+Rituximab+Cyclophosphamide+Doxorubicin+Prednisone) Patients who have received induction chemotherapy will be…
- Trial name
- NCT03616782
- Testing
- Ixazomib
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Ho Sup Lee
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Lymphoma, Mantle Cell Lymphoma
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells, either…
- Conditions
- Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, SLL
- Trial name
- VCR (NCT00980395)
- Testing
- rituximab, bortezomib, cladribine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Arizona
Mantle Cell Lymphoma
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
This is a randomized, open-label, multicenter, prospective study to compare the efficacy and safety of the combination of VcR-CAP to that of R-CHOP in participants who have newly diagnosed mantle cell lymphoma grade II, III or IV…
- Trial name
- NCT00722137
- Testing
- Rituximab 375 mg/m^2, Cyclophosphamide 750 mg/m^2, Doxorubicin 50 mg/m^2
- Where
- 150 sites in United States, Austria and 27 more
- Volunteers
- 487 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Mantle Cell Lymphoma
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is not curable with conventional therapy. This study sought to improve upon standard of care in newly diagnosed, untreated MCL patients who were transplant-eligible using drugs already established as…
- Trial name
- NCT01661881
- Testing
- Rituximab, Bendamustine, Cytarabine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Christine Ryan
Lymphoma
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
This phase I/II trial studies the side effects and best dose of temsirolimus when given together with cladribine and rituximab and to see how well it works in treating patients with newly diagnosed mantle cell lymphoma.
- Trial name
- NCT00787969
- Testing
- rituximab, cladribine, temsirolimus
- Where
- 144 sites in United States
- Volunteers
- 74 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00376961
- Testing
- rituximab, bortezomib, cyclophosphamide
- Where
- 147 sites in United States
- Volunteers
- 68 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma
Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00234026
- Testing
- gemcitabine hydrochloride
- Where
- 16 sites in Switzerland
- Sponsor
- Swiss Cancer Institute
Liver Lymphoma, Mantle Cell Lymphoma
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
This phase II trial compares three chemotherapy regimens consisting of bendamustine, rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating patients with newly diagnosed mantle cell…
- Trial name
- NCT04115631
- Testing
- Acalabrutinib, Bendamustine, Bendamustine Hydrochloride
- Where
- 504 sites in United States
- Volunteers
- 360 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Mantle Cell Lymphoma
A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study of parsaclisib plus BR versus placebo plus BR as first-line treatment of participants with newly diagnosed MCL.
- Trial name
- CITADEL-310 (NCT04849715)
- Testing
- parsaclisib, rituximab, bendamustine
- Sponsor
- Incyte Corporation
Mantle Cell Lymphoma
A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma
This is a phase 2, multicenter, open-label, active-controlled randomized trial to determine efficacy and safety of rituximab/bendamustine (RB) alternating with rituximab/bendamustine/cytarabine (RBAC) compared with standard RB…
- Trial name
- NCT05245656
- Testing
- RB/RBAC alternating, RB
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Kim, Seok Jin
Lymphoma
Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003311
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Mantle Cell Lymphoma
A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
Evaluation the efficacy and safety of Zanubrutinib + R-CHOP/R-DHAP for the treatment mantle cell lymphoma.
- Trial name
- Z+RCHOP/RDHAP (NCT06255704)
- Testing
- Zanubrutinib and RCHOP/RDHAP
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Shanxi Province Cancer Hospital
Mantle Cell Lymphoma, Newly-diagnosed Mantle Cell Lymphoma
Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL
This phase 2 trial studies the efficacy and safety of zanubrutinib plus rituximab followed by R-DHAOx (rituximab, dexamethasone, cytarabine and oxaliplatin) regimen then maintenance with zanubrutinib for newly-diagnosed Mantle…
- Trial name
- NCT04624958
- Testing
- Zanubrutinib and Rituximab, R-DHAOx, Zanubrutinib Maintenance
- Where
- 3 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Intermediate-to-High-Risk Mantle Cell Lymphoma, the Efficacy and Safety
The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL
A Single-Arm, Prospective Clinical Study Evaluating the Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined with Obinutuzumab in the First-Line Treatment of Newly Diagnosed Intermediate-to-High-Risk Mantle Cell Lymphoma
- Trial name
- NCT07548255
- Testing
- Sonrotoclax, Zanubrutinib Combined with Obinutuzumab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Ruijin Hospital
Mantle Cell Lymphoma
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
This phase II trial studies how well ibrutinib and rituximab given together with venetoclax and combination chemotherapy work in treating patients with newly diagnosed mantle cell lymphoma.
- Trial name
- NCT03710772
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center